期刊文献+

幼年皮肌炎合并软组织钙化临床分析

Clinical analysis on juvenile dermatomyositis combined with soft-tissue calcification
原文传递
导出
摘要 目的探讨幼年皮肌炎(JDM)合并软组织钙化临床特点。方法回顾性分析47例JDM患者合并软组织钙化(皮下钙化组)特点,并与89例非皮下钙化组患者(非皮下钙化组)对比。结果皮下钙化组Go,on征、肌挛缩和关节功能障碍比例高于非皮下钙化组[87.23%(41/47)比43.82%(39/89)、68.09%(32,47)比21.35%(19/89)],差异有统计学意义(P〈0.05);皮下钙化组发病后应用最大激素量(换算为泼尼松〉1.5mg/kg)、发病后应用免疫抑制比例及发病时肌酸激酶水平低于非皮下钙化组[17.02%(8/47)比68.54%(61/89)、25.53%(12/47)比88.76%(79/89)、(566.45±240.41)U/L比(1680.12±656.50)U/L],差异有统计学意义(P〈0.05)。结论JDM合并皮肤Gotton征者更易发生皮下钙化;皮下钙化患者发生肌挛缩和关节功能障碍概率高于非皮下钙化患者;对于发病时肌酸激酶并未明显升高者,或许更易发生皮下钙化;早期积极应用激素、免疫抑制剂治疗可以减轻或预防后期钙质沉着的发生或发展。 Objective To analyze the clinical features of juvenile dermatomyositis (JDM) combined with soft-tissue calcification. Methods Forty-seven patients with JDM combined with soft-tissue calcification (soft-tissue calcification group) were retrospectively analyzed, and they were contrasted with 89 patients with non-calcification (non-calcification group). Results The rates of Gotton signe, muscle contracture and joint dysfunction in soft-tissue calcification group were significantly higher than those in non-calcification group: 87.23% (41/47) vs. 43.82% (39/89) and 68.09% (32/47) vs. 21.35% (19/89), and there were statistical differences (P 〈 0.05). The dosage of glueocorticoid (conversion of prednisone measuring more than 1.5 mg/kg), rate of using immunodepressant, level of creatine kinase in soft-tissue calcification group were significantly lower than those in non-calcification group: 17.02% (8/47) vs. 68.54% (61/89), 25.53% (12/47) vs. 88.76% (79/89), (566.45 ± 240.41) U/L vs. (1 680.12 ± 656.50) U/L, and there were statistical differences (P 〈 0.05). Conclusions The patients with JDM combined with Gotton signe are more prone to soft-tissue calcification. The rate of muscle contraeture and joint dysfunction in soft-tissue calcification patients is significantly higher than that in non-calcification patients. For the patients whose creatine kinase are not obviously elevated, they are more prone to soft-tissue calcification. Early active application of glueoeortieoid and immunodepressant therapy can reduce or prevent the occurrence or development of late calciumdeposition.
出处 《中国医师进修杂志》 2015年第10期733-736,共4页 Chinese Journal of Postgraduates of Medicine
关键词 皮肌炎 回顾性研究 软组织钙化 Dermatomyositis Retrospective studies Soh-tissue calcification
  • 相关文献

参考文献7

  • 1Chiu SK,Yang YH, Wang LC, et al. Ten-year experience of juvenile dermatomyositis: a retrospective study [J]. J Microbiol Immunol Infect, 2007,40( 1 ) :68-73.
  • 2Paehman LM, Liotta-Davis MR,Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis:assoeiation with increased production of tumor necrosis factoralpha,disease duration,and pathologic calcifications [J]. Arthritis Rheum,2000,43 (10): 2368-2377.
  • 3Gunawardena H,Wedderburn LR,Chinoy H,et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis [ J ]. Arthritis Rheum, 2009,60(6) : 1807-1814.
  • 4Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at diseaseonset[ J ]. Rheumatology(Oxford) ,2014,53 (12) : 2204-2208.
  • 5Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile der matomyositis with calcinosis [J]. Rheumatology ( Oxford ), 2008,47 ( 6 ) : 877-880.
  • 6Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis : a study of composition and treatment [ J ]. J Pediatr, 2001,138(5 ) :763-766.
  • 7Hollar CB,Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis:a pilot study [J]. J Dermatolog Treat, 2004,15 ( 1 ) :35-39.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部